McIlrath & Eck’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
McIlrath & Eck's NBIX Position: Q3 2026 in Review
McIlrath & Eck increased its Neurocrine Biosciences (NBIX) stake by 9.7% in Q3 2026, buying an estimated $5.46K and bringing the position to 384 shares worth $54.5K. The position accounts for 0.01% of the portfolio, ranked #306.
McIlrath & Eck first reported a position in NBIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $59K in Q2 2026. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- McIlrath & Eck held 384 shares of Neurocrine Biosciences worth $54.5K as of Q3 2026.
- McIlrath & Eck bought 34 Neurocrine Biosciences shares in Q3 2026, an estimated $5.46K.
- Neurocrine Biosciences made up 0.01% of McIlrath & Eck's portfolio in Q3 2026, its #306 holding.
- McIlrath & Eck first reported a position in Neurocrine Biosciences in Q2 2026 and has held it in 2 quarters since.
- McIlrath & Eck's Neurocrine Biosciences position peaked at $59K in Q2 2026.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on McIlrath & Eck's 13F filing for Q3 2026, filed 17 Nov 2026.